Long-term treatment with finasteride either alone or in combination with doxazosin is associated with clinically significant reductions in total prostate volume in patients with lower urinary tract symptoms (LUTS) and BPH, regardless of baseline prostate size, data show.
Steven A. Kaplan, MD, professor of urology at Weill Medical College of Cornell University in New York City, and his colleagues studied 3,047 patients with LUTS who were randomized to receive placebo, doxazosin (4-8 mg), finasteride (5 mg), or both drugs daily. The patients were participants in the Medical Therapy of Prostatic Symptoms trial.
After an average of 4.5 years, finasteride led to a consistent reduction of about 25% in total prostate volume compared with placebo in men with small, moderate, and enlarged prostates at baseline, according to a report in The Journal of Urology (2008;180:1030-1032).
Continue Reading
